Internal Medicine, Medical Oncology · Duarte, CA
NPI
1497047195
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1500 Duarte Rd
Duarte, CA, 91010
Phone (626) 256-4673
Groups this clinician bills Medicare through
Medicare paid, 2024
$117K
1,026 services
Medicare patients, 2024
200
Average age 71
Drug cost, 2024
$1.2M
1,033 prescriptions
Company payments, 2025
$983
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wenge Wang was code 99215 (office e&m - established), 766 times for 145 patients. In total Wenge Wang billed 1,026 services in 10 codes, and Medicare paid $117K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 766 | 145 | $120.05 | $92K |
| 99214 Office E&M - Established | Facility | 144 | 81 | $80.04 | $12K |
| 99205 Office E&M - New | Facility | 46 | 46 | $142.82 | $6,570 |
| 99215 Office E&M - Established | Office | 20 | 19 | $145.20 | $2,904 |
| 99214 Office E&M - Established | Office | 18 | 15 | $101.32 | $1,824 |
| 99497 Care Management/Coordination | Facility | 13 | 11 | $64.68 | $841 |
By year: 2022 $85K for 776 services; 2023 $99K for 926 services; 2024 $117K for 1,026 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wenge Wang prescribed most often to Medicare patients was Ondansetron Hcl, with 83 prescriptions and refills. In total Wenge Wang wrote 1,033 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ondansetron Hcl Generic | 83 | 83 | 45 | $2,925 |
| Dexamethasone Generic | 67 | 82 | 47 | $2,038 |
| Prochlorperazine Maleate Generic | 65 | 65 | 41 | $808 |
| Eliquis Apixaban | 54 | 56 | 13 | $34K |
| Levothyroxine Sodium Generic | 53 | 93 | 18 | $398 |
| Famotidine Generic | 49 | 58 | 24 | $209 |
| Letrozole Generic | 44 | 84 | 17 | $747 |
| Everolimus Generic | 42 | 42 | Under 11 | $257K |
| Gabapentin Generic | 40 | 57 | 15 | $547 |
| Lynparza Olaparib | 38 | 38 | Under 11 | $362K |
| Amlodipine Besylate Generic | 35 | 59 | 12 | $92.87 |
| Lorazepam Generic | 35 | 35 | 21 | $88.5 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 33 | 33 | 16 | $351 |
| Losartan Potassium Generic | 30 | 54 | Under 11 | $180 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 21 | 22 | 16 | $230 |
Brand drugs: - claims; generic drugs: 880 claims; opioid claims: 46.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wenge Wang $983 ($983 in general payments such as food, travel and fees) from 5 companies. The largest payer was Abbvie Inc. with $908.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.